Full Breakdown
Pfizer Posts Q2 2026 Earnings Beat, Expands Cost-Saving Program Amid Post-COVID Revenue Shift
8/4/2026, 8:39:18 PM
Core Event
In early August 2026, Pfizer released its second-quarter results, showing a net loss of four cents per share but an adjusted profit of 77 cents, beating expectations. Revenue hit $15 billion, driven by Eliquis ($2.43 billion, up 19 %) and Padcev ($667 million, up 23 %). The company added $2.5 billion in cost-saving initiatives, extending its restructuring through 2029.
Background & Context
Pfizer’s COVID-19 products—Comirnaty vaccine and Paxlovid antiviral—are in a low-incidence phase, prompting a cut in the COVID-related revenue outlook to $4 billion for the year, down from about $5 billion. The firm continues its “Realigning Our Cost Base” program launched in October 2023 to offset declining pandemic-era earnings and upcoming patent expirations.
Data & Statistics
| Metric | Figure | Source |
|---|---|---|
| Full-year revenue outlook (2026) | $60.5 billion – $62.5 billion | CNBC, Reuters |
| Q2 2026 total revenue | $15 billion | Reuters, Biospace |
| Eliquis Q2 sales | $2.43 billion (19 % YoY) | CNBC, Reuters |
| Padcev Q2 sales | $667 million (23 % YoY) | Reuters, Biospace |
| Additional cost-saving target | $2.5 billion (total net savings $9.7 billion through 2029) | Reuters |
| Impairment charge | $3.8 billion on experimental lung-cancer drug sigvotatug vedotin | Reuters |
Official Statements & Responses
Interim CFO Cecile Guegan said the modest COVID outlook reflects “low COVID-19 incidence” limiting Paxlovid use and that most Comirnaty sales are expected toward year-end.
Verbatim Quotes
- “With our strong performance through the first half of the year and our ongoing productivity enhancement discipline, we remain confident in our business,” — Pfizer CEO Albert Bourla
Conflicting Reports & Gaps
Reuters cites total net savings of $9.7 billion through 2029, while Biospace reports $6.7 billion. Both agree on the $2.5 billion addition. The COVID-related revenue outlook is given as a $4 billion range by CNBC; Reuters does not separate the COVID figure, only the combined full-year range.
What’s Next
Near-term catalysts include late-stage trial data for the lung-cancer antibody-drug conjugate sigvotatug vedotin (tested with Merck’s Keytruda) and results from the Phase 1 trial of oral GLP-1 peptide MET-2240 acquired via the $10 billion Metsera purchase. Analysts will watch whether these pipeline developments can offset revenue pressure from expiring patents and reduced COVID product sales.
